Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel

摘要: Topical 3% diclofenac in 2.5% hyaluronic acid (HA) gel (diclofenac HA gel; Solaraze) is an NSAID approved for the treatment of actinic keratoses (AK). The efficacy (0.5g applied twice daily to each 5cm x area) patients with AK has been evaluated three randomized, double-blind, vehicle-controlled trials. In trial, was assessed 30 days after end because earlier study revealed that resolution lesions greater when measured a 4 week interval, rather than at treatment. two fully published multicenter trials, there no difference baseline characteristics groups. further single center (not yet published), randomized had significantly higher mean number target compared vehicle. studies, increased duration. When vehicle recipients, significant improvements total lesion scores (TLNS), cumulative (CLNS), patient global improvement indices (PGII) and investigator (IGII) were obtained treated 60 90 but not gel. Fifty percent (vs 20% recipients) 33% those 10%) TLNS CLNS zero follow-up. third which days, statistically proportion or However, controlling by calculating change from counts, lower recipients Pruritus most frequently reported adverse event all trials incidence generally similar conclusion, produces reductions lesions, can produce complete clearance days. product well tolerated did serious cosmetic effects clinical Thus, represents useful addition array pharmacologic treatments available AK.